1 / 30

Gout

Gout. Dr. Pamela Leventis Consultant Rheumatologist Epsom & St. Helier NHS Trust. A disease of Kings. GOUT – Outline. Epidemiology Diagnostic difficulties Management (EULAR/BSR guidelines) Gout – Top tips. Epidemiology. Commonest Inflammatory Arthritis in men

nevina
Download Presentation

Gout

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gout Dr. Pamela Leventis Consultant Rheumatologist Epsom & St. Helier NHS Trust

  2. A disease of Kings

  3. GOUT – Outline • Epidemiology • Diagnostic difficulties • Management (EULAR/BSR guidelines) • Gout – Top tips

  4. Epidemiology • Commonest Inflammatory Arthritis in men • Mean UK prevalence – 1.4% • Prevalence increases with age • >7% of men >75 yrs, >4% of women >75 yrs (Mikuls et al., 2005)

  5. Hyperuricaemiathe biggest risk factor for gout Underwood M BMJ 2006;332:1315-1319 • Laboratory reference ranges differ between populations – usually 2SDs above/below mean • Theoretical Saturation of serum urate – 360μmol/l

  6. Pathogenesis Gout is due to extracellular deposition of uric acid crystals in joints Synovial fluid examination under polarised light – negatively birefringentcrytals

  7. Gout Diagnosis

  8. A first hand description The victim goes to bed and sleeps in good health. About 2 o'clock in the morning, he is awakened by a severe pain in the great toe; more rarely in the heel, ankle or instep. This pain is like that of a dislocation, and yet the parts feel as if cold water were poured over them. Then follows chills and shiver and a little fever. The pain which at first moderate becomes more intense. With its intensity the chills and shivers increase. After a time this comes to a full height, accommodating itself to the bones and ligaments of the tarsus and metatarsus. Now it is a violent stretching and tearing of the ligaments-- now it is a gnawing pain and now a pressure and tightening. So exquisite and lively meanwhile is the feeling of the part affected, that it cannot bear the weight of bedclothes nor the jar of a person walking in the room. Thomas Sydenham 1683

  9. Podagra ‘seizing the foot’ >97% specificity for gout in context of supportive clinical presentation and hyperuricaemia (Rigby and Wood, 1994)

  10. Why can gout be difficult to diagnose? • Atypical Joint/tendon/bursa involvement • Pre-existing joint pathology • Gout- a great mimic Roddy E, Doherty M. Gout. In: Warburton L (ed). Musculoskeletal disorders in primary care. London: RCGP. In press 2011. Roddy E. (2011) Arthritis Research UK

  11. Gout or Septic Arthritis?

  12. Gout or Cellulitis?

  13. Gout or Rheumatoid arthritis?

  14. Diagnostic ambiguity • Gout flare can be associated with • Normal Serum urate (~10%) • ?serum urate lowered during acute phase response (Urano et al., 2002) • Gout triggered by drop in serum urate • Mild Leucocytosis • Low grade fever • Normal X-ray • Synovial fluid examination • 63-78% sensitivity – degree of operator dependence/sample quality (Swan et al., 2002) • Crystals may co-exist with sepsis (case series 30 patients – Yu et al. (2003))

  15. Gout Management

  16. Goals of Therapy 1. Minimise morbidity of acute flare 2. Prevent future flares, and thereby prevent joint damage and disability • Patient Education and Lifestyle changes • Pharmacological Prophylaxis if indicated

  17. ManagementAcute Gouty Flare BSR Guidelines (Jordan et al., 2007) • 1st line • Full dose NSAID continued for 1-2 weeks – unless contraindication • If risk of peptic ulcer disease – co-prescribe Proton pump inhibitor • Alternatively • Colchicine 500μg bd-qds (higher dosing associated with disproportionate toxicity) • Intra-articular corticosteroid injection for monoarticular flare • Oral prednisolone for severe/polyarticular flare • Urate lowering therapies should not be commenced or stopped during acute gout

  18. ManagementLong term ProphylaxisNon – pharmacological • Diet (www.ukgoutsociety.org) • Alcohol < 21 U/wk ♂, <14 U/wk ♀ • Obesity – aim for ideal BMI • Exercise • Smoking • Strong association between gout and the metabolic syndrome (Choi et al., 2007) • Annual Screen- BP/Weight/fasting lipid profile/glucose

  19. ManagementLong term Prophylaxis - Pharmacological When to initiate urate lowering therapies? • EULAR/BSR Guidelines • Uniform agreement for prompt treatment in: • Severe gout with X-ray changes • Tophaceous deposits • Chronic kidney disease • Nephrolithiasis • Urinary uric acid excretion exceeding 1100 mg/day (6.5 mmol) • Otherwise shared decision with patient re: risks/benefits of treatment/no treatment • BSR guidelines suggest initiation of treatment if ≥ 1 further attack within 12 months

  20. ManagementLong term Prophylaxis - Pharmacological 1st line urate lowering therapy (BSR/EULAR guidelines) • Uricostatics – Xanthine oxidase inhibitor • Allopurinol – starting dose 100mg od • Consider Febuxostat first line in patients with chronic kidney disease Jordan et al., (2007)

  21. ManagementLong term Prophylaxis - Pharmacological • Aim for plasma urate • <300μmol/l (BSR guidelines) • median [urate] for men in UK • <360 μmol/l (EULAR guidelines) • saturation point serum urate • Commence at least 2 weeks following resolution of acute attack • Consider low dose colchicine – 500μg od/bd for up to 6 months following initiation • 77% patients flare within 6 months of initiating allopurinol (Borstad et al. 2004)

  22. Allopurinol dosing • Increase every 2-4 weeks by 100mg until target serum urate achieved. Maximum 900mg/day. • Start low – go slow approach recommended • To reduce likelihood of triggering attack • To minimise risk of toxicity (AHS) • Emphasis on target value

  23. Allopurinol Hypersensitivity Syndrome • 1:300 patients • At risk groups: Elderly and Renal Impairment • Erythematous desquamating rash • Fever • Hepatitis • Eosinophilia • Worsening renal function • 20% mortality (Lee et al., 2008)

  24. ManagementLong term Prophylaxis - Pharmacological 2nd line – failure to reach target serum urate • If normal renal function • uricosuric(Contraindicated if history of nephrolithiasis) • Sulphinpyrazone- 200-800mg/day • Probenecid – named patient basis • Benzbromarone if mild – moderate renal impairment (GFR 30-60ml/min) – named patient basis • Or combination therapy • Losartan and Fenofibrate – weak uricosurics

  25. ManagementLong term Prophylaxis - Pharmacological • Febuxostat currently approved by NICE if: • adverse effects on allopurinol • OR further dose escalation contra-indicated with suboptimal serum urate • most common side effects • diarrhoea, nausea, headache, abnormal LFTs, rash

  26. Renal Uric acid Excretion • Urinary uric acid:creatinine ratio to diagnose over excretors • Should be determined in : • Young patients diagnosed with gout <25 yrs • Patients with a family history of young onset gout • Patients with renal calculi

  27. BSR gout treatment algorithm Jordan et al., 2007

  28. Future Treatments • Uricases – convert urate to allantoin • ?debulkingurate load in tophaceous gout • IL-1 antagonists to treat severe acute flares • Anakinra, Canakinumab

  29. Gout – Top Tips • Gout is very rare in pre-menopausal women, referral advised. • Hyperuricaemia + joint inflammation ≠ gout • Serum urate is often normal during a gouty flare. • X-rays are not useful in acute/early gout. • Avoid any changes to Allopurinol dosing during or within a fortnight of an acute flare of gout. • Commonest cause for Allopurinol failure is non compliance.

  30. REFERENCES • Mikuls TR, Farrar JT, Bilker WB et al. Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis (2005), 64:267-272. • Underwood M. Diagnosis and management of gout. BMJ. 2006; 332: 1315-1319 • Lee H Y, Ariyasinghe J T N, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008; 49(5) : 384 • Borstad GC, Bryant LR, Abel MP et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol (2004), 31:2429-2432 • Zhang W, Doherty M, Pascual E et al. EULAR evidence based recommendations for gout. Parts I and II. Ann Rheum Dis (2006), 65:1301-1324 • Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (2007), 46:1372-1374 • http://www.nice.org.uk/nicemedia/pdf/TA164Guidance.pdfFebuxostat for the management of hyperuricaemia in people with gout

More Related